mash prevalence and unmet needs

Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a silent epidemic, affecting millions globally and progressing to fibrosis, cirrhosis, and liver cancer if untreated. With US prevalence at ~14 million and rising incidence worldwide, urgent interventions are needed. The recent rebranding from NASH to MASH underscores the metabolic roots of the disease, enabling better diagnosis, reducing stigma, and reshaping therapeutic strategies.

Despite recent approvals, REZDEFFRA (THR-β agonist, 2024) and semaglutide (GLP-1 receptor agonist, 2025), treatment gaps remain. A robust pipeline of over 45 clinical-stage therapies, including GLP-1/dual agonists, FGF21 analogs, and THR-β agonists, signals the dawn of a multi-mechanism era. F2–F3 fibrosis stages have become the regulatory and clinical “sweet spot,” guiding targeted interventions for maximal impact. Strategic innovation, combination therapies, and biomarker-driven approaches are set to define the next wave of breakthroughs.

Why This Matters:

• MASH is no longer an orphan disease; it’s a high-stakes, rapidly evolving therapeutic frontier.
• Multi-mechanism strategies will replace single-pathway treatments.
• Precision hepatology—matching therapies to fibrosis stage, comorbidities, and metabolic profiles—will drive differentiation and clinical success.
• Non-invasive diagnostics and real-world evidence are critical for adoption and long-term disease management.

Download the full whitepaper to explore market forecasts, pipeline insights, regulatory strategies, and the competitive landscape shaping the future of MASH therapy.